Role of G Protein-coupled Orphan Receptors in Intestinal Inflammation
Authors:
- Martin StorrMSMartin Storr
- Marta ZielińskaMZMarta Zielińska
- Jakub FichnaJFJakub Fichna
- 1 March 2015
- journal article
- review article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 21 (3) , 666-673
Abstract
A large number of proteins were classified into the family of G protein-coupled receptors (GPCRs). Based on their characteristic serpentine domain, they are called 7 TM receptors. Presently, their ligands and physiological functions remain unknown. In this review, we summarize what is known on these receptors and discuss the potential use of these orphan GPCRs (GPRs) in the induction or maintenance of remission in inflammatory bowel diseases. We focus on GPRs 30, 41, 43, 55, 119, and 120, where scientific evidence supports a potential role in intestinal inflammation.Keywords
This publication has 127 references indexed in Scilit:
- Evidence That the G Protein–Coupled Membrane Receptor GPR30 Contributes to the Cardiovascular Actions of EstrogenGender Medicine, 2011
- Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivityThe Journal of Steroid Biochemistry and Molecular Biology, 2011
- The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitmentInflammatory Bowel Diseases, 2011
- The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular functionVascular Pharmacology, 2011
- GPR120 Is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-inflammatory and Insulin-Sensitizing EffectsCell, 2010
- Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43Nature, 2009
- Receptors for acylethanolamides—GPR55 and GPR119Prostaglandins & Other Lipid Mediators, 2009
- Non-genomic regulation of vascular cell function and growth by estrogenMolecular and Cellular Endocrinology, 2009
- Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosisJournal of Neuroimmunology, 2009
- In vivo effects of a GPR30 antagonistNature Chemical Biology, 2009